Highlights from ExL Pharma's Site Selection, Activation & Communication

34
ExL Pharma’s Site Selection, Activation & Communication Washington, D.C. February 1-2, 2010

description

 

Transcript of Highlights from ExL Pharma's Site Selection, Activation & Communication

  • 1. ExLPharmas Site Selection, Activation & Communication
    Washington, D.C.
    February 1-2, 2010
  • 2. Site Selection Criteria: Why Making the Right Choice is More Important Today Than Ever Before
  • 3. Clinical Development Program Background
    Program/Project and Protocol Timelines
    Impact to Program/Project Cost and Timelines
    Marketing Considerations Opportunities
    Criteria for Selection
    Sponsor/CRO Considerations
    Site/SMO Considerations
    Academia Considerations
    Site Selection Criteria Topics
  • 4. Clinical Development from IND to NDA
    250 to 500 million USD to complete clinical
    5 to 7 years timeline for clinical
    Equates to:
    35.25 to 71.5 million USD per year to run clinical
    100K to 200K per day during clinical development
    Development Key Points
  • 5. $$- TIME IS MONEY -$$
    Every day the trial is operating is 100 to 200k USD operational cost.
    Development Key Points
  • 6. Marketing Considerations and Opportunities
    Blockbuster drug can generate 2-5 million USD per day in sales revenue
    Windows for marketing a drug are dynamic
    First to market wins market share
    Claritin OTC versus Zyrtec OTC example
    Market share decreases dramatically based on tier approval; First in Class, First to Market, 2nd to Market etc.
    Development Key Points
  • 7. $$- TIME IS MONEY -$$
    Delays in Time to Market
    2 to 5 million per day
    700 to 1,500 million per year
    Decreases in market share from 75/80% to 25%
    Development Key Points
  • 8. Corporate Fiscal Management
    Budgets are developed for 3-5 year plans
    Forecasts are performed yearly and quarterly
    Development program budgets span across almost a decade
    Shifting funding from one year or quarter may mean raiding funds for other clinical programs, acquisitions, mergers, bonuses, pay increases, etc.
    Executive management take very seriously delays that impact corporate investor relations and solvency
    Development Key Points
  • 9. Impact of Clinical Development Program Delays
    Delays impact traditional development models, employees, stakeholders, investors, and the public.
    Paradigm shifts: Many companies are outsourcing clinical programs to CROs and Clinical Service Providers.
    Mergers/Acquisitions: Many companies are undergoing mergers to consolidate costs and create synergies.
    Layoffs: Companies are more often cutting back on employee debt load to conserve finances for development and solvency.
    Development Key Points
  • 10. $$- TIME IS MONEY -$$
    Operational Costs
    Marketing and Market Opportunity Costs
    Corporation Cash Flow and Solvency
    Mergers, Layoffs, and Paradigm Shifts
    Development Key Points
  • 11. Clinical Development Program Timelines
    Clinical endpoints set by FDA, EMEA, and other CAs.
    Treatment duration defined by endpoints selected.
    These factors are not dynamic and dictate length of program, project, and protocol duration.
    Dynamic influencers are study start up, length of recruitment, data cleaning, data analysis, NDA package assembly, and NDA submission.
    Study start-up and recruitment are low hanging fruit for timeline compression also areas for dramatic delays.
    Development Key Points
  • 12. Timeline Compression or Delay
    Study Start-up is critical to program timelines.
    Site Selection.
    Site budget/contract negotiations.
    Site approval and activation.
    First patient in (FPI).
    Patient recruitment period is critical to timelines.
    Last patient in (LPI).
    Last patient out (LPO).
    Timelines
  • 13.
  • 14. Site Selection is critical to timelines
    Rapid contract and budget negotiations.
    Rapid site IRB approvals.
    Rapid site activation.
    Hard hitting recruitment.
    Rapid FPI
    All equate to a shortened program timeline OR
    Significant study delays = program delays
    Timelines
  • 15. $$- TIME IS MONEY -$$
    Shortening study start up by one day
    = 100-200K operational costs.
    = 2-5 million marketing or sales revenue.
    Delays result in similar losses
    Timelines = Costs
  • 16. Sites previously used by sponsor speed processes.
    Sites that have standardized contracts/budgets.
    Eliminates multi-pass review with Legal and Finance.
    Accurate program per patient cost projections.
    Sites that rapidly negotiate contracts/budgets.
    Sites that can use central IRBs or have rapid locals.
    Study Site Selection Criteria
  • 17. Sites with that know/experienced with disease indication.
    Sites that are experienced in clinical research.
    Sites that are known to be hard hitting recruiters.
    Sites with internal study marketing personnel.
    Sites that have large PT DBs.
    Study Site Selection Criteria
  • 18. Negotiate MSAs with centers used often especially acadaemia.
    Use sites with Hx of rapid negotiations, activation, and FPI, and LPI.
    Limit number of KOL/academic centers slow to start and low numbers.
    Using centers often has benefit of no or short PSV.
    Sponsor/CRO Considerations
  • 19. Use sites that are hungry for trials, call often, respond rapidly, provide marketing material.
    Maintain DB of sites with solid performance metrics, share across TAs, update often.
    Contract CRAs know the good centers listen to them.
    Sponsor/CRO Considerations
  • 20. Maintain internal performance metrics and hold staff accountable.
    Have accurate and concise study site marketing materials
    Hx performance metrics,
    Breakdown of disease specific Pt DB information,
    List networks with local referring Docs/practices/centers.
    Gain exemptions to use central IRBs if using a local.
    Develop and maintain standardized budgets and contracts.
    Site/SMO Considerations
  • 21. Develop and maintain standardized pull-n-sendregulatory packets for rapid submission.
    Keep pt DB up to date build and maintain relationship with clinic and research patients, communicate often via newsletters, mailings, etc.
    Train or hire marketing coordinator for study promotion.
    Site/SMO Considerations
  • 22. Develop and maintain great relationships with Legal, Grants/Contracts, IT, IP, and local IRBs.
    Work to educate and inform above that centers must have rapid turn around times for Sponsored trials.
    Obtain local IRB exemptions if at all possible.
    Academia Considerations
  • 23. Develop and maintain referral partners within center, town, region, state; communicate often.
    Be responsive to Sponsor/CROs; return calls and emails immediately, regardless of status changes.
    Develop execution/action oriented attitude within staff and academic center must have can-do attitude to capture sponsored trials.
    Put out fires immediately if Sponsor appears frustrated, they are!!
    Academia Considerations
  • 24. SITE PERSPECTIVE:An In-depth Look at What Drives Site Decisions and Strategies for Putting Sites in Position for Success
  • 25. Inaccurate Feasibility Questionnaires
    Unrealistic enrollment expectations
    Inaccurate enrollment time lines
    Research Staff Lacking Training and Experience
    Inexperienced PIs
    Not Reading the Protocol in its Entirety
    Lack of knowing study related procedures
    Missed details of inclusion and exclusion criteria
    25
    Initial Practices that Hamper Site Success
  • 26. CTA Review
    Budget Negotiation
    IRB Submission/Approval
    ID of Sub-Contracting
    Required EDC Training
    Scheduling Conflicts with
    Site Initiation Visit
    26
    Common Reasons for Delays in Site Activation
  • 27. 27
    Factors Most Often Causing Study Delays
    Source: CenterWatch Survey of Investigative Sites in the U.S.: 2009 (n=950)
  • 28. 28
    Faltered Execution at Study Start
  • 29. Internal Preparation Practices:
    Unique feasibility assessment
    PI training/qualification
    Access to facilities for specific procedures
    Lasting first impressions for site selection visits
    Budget development tool
    Streamlined site activation
    29
    Steps to Effectively Prepare for Site Success
  • 30. 30
    Achieve Fast Site Activation
    Improve
    Efficiency
    Within
    Timelines
  • 31. Time Is of The Essence
    Budgets & Agreements:
    Regulatory submissions:
    Preparing IRB submissions
    Know whats required (signatures, ads, etc.)
    Legal review of agreements/ICF
    Simultaneous budget negotiation
    31
  • 32. Compliance
    Educate often and be current on new policies for State and National coverage in Clinical Trials
    Systematic Tracking of Enrollment & Revenue
    Use study management software to:
    Track subject enrollment and study visits
    Better revenue collections
    Maintain secure subject data
    Track study milestones and payables
    32
    In Addition
  • 33. 33
    Conclusion
    The Key to Your Success is:
    • Create and utilize tools
    • 34. Deliver What You Promise
    • 35. Be prepared and knowledgeable
    • 36. Leave a good first impression